Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.605 USD | +1.83% | -11.19% | +131.72% |
05-13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
05-08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+131.72% | 607M | |
+29.93% | 48.16B | |
-0.66% | 41.73B | |
+43.79% | 41.03B | |
-5.31% | 28.77B | |
+10.04% | 25.59B | |
-22.49% | 18.96B | |
+9.16% | 12.92B | |
+28.71% | 12.03B | |
-2.31% | 11.77B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Cantor Fitzgerald Starts Mind Medicine at Overweight With $3 Price Target